Synlogic announces nature publication demonstrating novel application of synthetic biotic platform

Cambridge, mass. , oct. 12, 2021 /prnewswire/ -- synlogic, inc. (nasdaq: sybx), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the publication in nature of preclinical research with live biotherapeutic products designed using the company's synthetic biotic™ platform.
SYBX Ratings Summary
SYBX Quant Ranking